Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk (Diabetes, Obesity and Metabolism)
Diabetes News
Category: Hepatology
An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care
From the perspectives of health practitioners, there is a gap in clinical practice for the implementation of clear, evidence-based guidelines for NAFLD in people with T2D. By focusing on comorbidity prevention and integrating NAFLD as a diabetes complication to be addressed during established cycles of care, many barriers to implementing a NAFLD pathway in primary care could be overcome (Diabetic Medicine)
The Association Between Vitamin D and Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease: An Observational Cross-Sectional Study
This study suggests that T2DM people with BMI > 23kg/m2 were more susceptible to NAFLD by vitamin D deficiency and that it is necessary to maintain optimal serum vitamin D levels in this population (Metabolic Syndrome and Obesity)
Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database
Elevated liver enzymes are common in patients with T2D and clearly correlate with a higher prevalence of clinically relevant comorbidities. Assessing liver enzymes should be standard clinical routine in T2D due to a possible predictive role for comorbidities and complications (Diabetes, Obesity and Metabolism)
Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials
Treatment with SGLT2 inhibitors improves liver structure and function in patients with T2D. This meta-analysis suggests that SGLT2 inhibitors are a promising pharmacological approach for treatment of NAFLD (Diabetes/Metabolism Research and Reviews)
Impact of SGLT2 inhibitors in comparison to DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
In comparison to DPP4i, SGLT2i may improve survival for patients with cirrhosis who require additional pharmacotherapy for DM beyond metformin, but confirmatory studies are necessary (Diabetes, Obesity and Metabolism)
The association of laminin levels with insulin resistance and non-alcoholic hepatosteatosis
Our study results suggest that, although there is no exact link between laminin and non-alcoholic hepatosteatosis, serum laminin levels are lower in patients with insulin resistance by regulating the insulin effect through integrins (Diabetes and Metabolic Syndrome)
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins (Metabolism – Clinical and Experimental)
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial
Statin therapy is safe in patients with prediabetes/T2DM and NASH. Given their high cardiovascular risk, statin therapy should be encouraged in this population (JCEM)
Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study
Our findings demonstrate that prediabetic patients show a lower phenotypic flexibility after external aggression, such as OFTT compared with nondiabetic patients. The postprandial response increases progressively according to non-diabetic, prediabetic and type 2 diabetic state and it is higher in patients with liver insulin-resistance. To identify this subgroup of patients is important to treat more intensively in order to avoid future cardiometabolic complications (Cardiovascular Diabetology)
The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
Fatty Liver Index assessed nonalcoholic fatty liver disease (FLI-NAFLD) was present in the majority of T2DM patients of our sample and metabolic derangement, not alcohol consumption, was mainly associated with the disease. FLI-NAFLD patients have a worse metabolic profile (Journal of Diabetes Research)
Assessment of the relation between non-alcoholic fatty liver disease and diabetic complications
NAFLD combined with type 2 diabetes is associated with the presence of significant coronary artery disease and hypertension (Journal of Diabetes Investigation)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies (The Lancet)
Effect of T2D on risk of hepatocellular carcinoma in chronic Hep C
T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN (Hepatology)
Glycosmedia is also available as an App: